ORAGENICS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Grant revenue | $37,653 | $131,521 |
| Operating expenses: | ||
| Research and development | 15,490,604 | 10,072,684 |
| General and administrative | 5,451,952 | 4,479,605 |
| Total operating expenses | 20,942,556 | 14,552,289 |
| Loss from operations | (20,904,903) | (14,420,768) |
| Other income (expense): | ||
| Interest income | 210,394 | 135,900 |
| Interest expense | (30,591) | (15,103) |
| Miscellaneous income | 69,363 | 11,582 |
| Total other income, net | 249,166 | 132,379 |
| Loss before income taxes | (20,655,737) | (14,288,389) |
| Income tax benefit | — | — |
| Net loss | $(20,655,737) | $(14,288,389) |
| Basic and diluted net loss per share | $(9.18) | $(7.11) |
| Shares used to compute basic and diluted net loss per share | 2,249,694 | 2,009,234 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.